1-800-818-6434info@purehealthcorpus.com
Ruby of the Sea® oil
Calanus Finmarchicus is an arctic zooplankton found in the pristine Norwegian sea. This all natural Calanus® oil is shown to increase energy and endurance and may reduce the risks of heart disease.

A published study by the British Journal of Nutrition on how Calanus oil improves metabolism

Abstract 

The aim of the present study was to investigate the effects of oil extracted from the zooplankton Calanus finmarchicus (Calanus oil) on diet-induced obesity and obesity-related disorders in mice. C57BL/6J mice fed a high-fat diet (HFD, 45 % energy from fat) exhibited increased body weight and abdominal fat accumulation as well as impaired glucose tolerance compared with mice fed a normal chow diet (10 % energy from fat). Supplementing the HFD with 1·5 % (w/w) Calanus oil reduced body-weight gain, abdominal fat accumulation and hepatic steatosis by 16, 27 and 41 %, respectively, and improved glucose tolerance by 16 %. Calanus oil supplementation reduced adipocyte size and increased the mRNA expression of adiponectin in adipose tissue. It also reduced macrophage infiltration by more than 70 %, accompanied by reduced mRNA expression of pro-inflammatory cytokines (TNF-a, IL-6 and monocyte chemotactic protein-1). The effects of Calanus oil were not only preventive, but also therapeutic, as the oil proved to be beneficial, regardless of whether the supplementation was started before or after the onset of obesity and glucose intolerance. Although the present study cannot pinpoint the active component(s) of the oil, there is reason to believe that the n-3 fatty acids EPA and DHA and/or antioxidants are responsible for its beneficial effects. It should be noted that the concentration of n-3 fatty acids in the Calanus oil diet was considerably lower than the concentrations used in similar studies reporting beneficial effects on obesity and obesity-related abnormalities.


Discussion 

Sedentary lifestyle and increased energy intake have resulted in a dramatic rise in the prevalence of obesity, the metabolic syndrome and insulin resistance, conditions correlating strongly with abdominal obesity(1). Abdominal obesity represents a much higher risk factor for mortality and morbidity in humans than general obesity(14), and individuals accumulating large amounts of abdominal fat are particularly prone to developing diabetes and CVD(1,15). Abdominal obesity is also associated with a local low-grade inflammatory response, and there is robust evidence for a mechanistic link between inflammation and insulin resistance(4–6,12). The main findings of the present study are that oil from the zooplankton C. finmarchicus, given as a minor food supplement to diet-induced obese mice, attenuates the deposition of intraabdominal fat, reduces liver steatosis and improves glucose tolerance. Calanus oil also decreases the inflammatory status in intra-abdominal adipose tissue.


References:

Anje C. Ho¨per1 †, Wahida Salma1 †, Ahmed M. Khalid1 , Anne D. Hafstad1 , Selene J. Sollie1 , Jan Raa2 , Terje S. Larsen1 and Ellen Aasum1. Cardiovascular Research Group, Department of Medical Biology, Faculty of Health Sciences, Institute of Medical Biology, University of Tromsø, N-9037 Tromsø, Norway 2 Hasselhaugveien 30, 0851 Oslo, Norway. British Journal of Nutrition